Giselle Sholler, Division Chief of Pediatric Hematology/Oncology/BMT at Penn State Health, shared a post on LinkedIn:
“The FDA is requesting information on potential priority disease areas and potential candidates for drug repurposing, with a focus on FDA-approved drugs. This is an incredibly important and timely topic as many of us in pediatric oncology face challenges such as access to medications, age limits for our trials, limiting access for our pediatric patients.
Please share your thoughts – we are so appreciative that the FDA is wanting to listen and share in this discussion.”
Other articles featuring Giselle Sholler on OncoDaily.